Synaffix, ABL Bio partner to develop bispecific ADCs
Lonza company Synaffix has signed a licensing agreement with ABL Bio for the development of bispecific antibody drug conjugates (ADCs).
Lonza company Synaffix has signed a licensing agreement with ABL Bio for the development of bispecific antibody drug conjugates (ADCs).
Salipro Biotech and Sumitomo Pharma have entered into a research partnership for advancing a drug discovery programme.
RaQualia Pharma’s sublicensee United Italian Trading (UITC) has launched the tegoprazan drug for the treatment of gastroesophageal reflux disease (GERD), in Singapore.
Innovac Therapeutics has raised $18m in Series Pre-A financing for funding the development of its lead programmes and manufacturing capabilities.
Allucent has received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to expedite clinical research and development of next-generation booster vaccines for Covid-19.
Daiichi Sankyo has announced its decision to shut down its Japanese research and development (R&D) subsidiary to further strengthen its capabilities.
Precision-medicine company Solu Therapeutics has raised $31m in seed financing to develop the Cytotoxicity Targeting Chimera (CyTaC) platform and drug candidates.
Viatris and Kindeva Drug Delivery have launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol to treat certain asthma and chronic obstructive pulmonary disease (COPD) patients.
The China National Medical Products Administration (NMPA) has accepted and granted priority review to Overland ADCT BioPharma’s biologics license application (BLA) for ZYNLONTA (loncastuximab tesirine-lpyl).
Generic and biosimilar medicines provider Sandoz has introduced a global action plan to provide patients with quick access to biologic medicines.